SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 5/22/2017 1:30:50 PM - Followers: 138 - Board type: Free - Posts Today: 16

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AUPH
Current Price
Volume:
Bid Ask Day's Range
PostSubject
#2943  Sticky Note There is a faction on another public forum puravida 04/22/17 04:20:15 PM
#3869   his attitude would not make him a good roadie cervelo 05/22/17 01:30:49 PM
#3868   He needs a cervello to do that. Maciste 05/22/17 12:40:19 PM
#3867   I like to follow the money!! If Robert Pittkid 05/22/17 12:29:40 PM
#3866   think harder cervelo 05/22/17 11:58:33 AM
#3865   I've been thinking of that. biotech_researcher 05/22/17 11:54:19 AM
#3864   If you are so worried maybe now is cervelo 05/22/17 11:50:57 AM
#3863   You can't compare the cost profiles of the SvsB 05/22/17 11:22:43 AM
#3862   That's funny! Hotrodder1 05/22/17 10:40:02 AM
#3861   Well, I've never own a company with only biotech_researcher 05/22/17 10:25:52 AM
#3860   This is from the quarterly report headlines. Pencow 05/22/17 09:54:44 AM
#3859   Vid, they ALWAYS say they have enough funds, biotech_researcher 05/22/17 09:52:26 AM
#3857   What r u talking about AUPH has lucylives 05/22/17 07:51:48 AM
#3856   As I recalled Glickman did state they have vidpok45 05/22/17 07:45:00 AM
#3855   trying to brush up on my math skills- moosedogger 05/22/17 07:14:41 AM
#3854   So dilution is the only way to get tiv111 05/22/17 06:18:10 AM
#3852   How about look at Auph's burn rate not Lunacy 05/21/17 08:43:47 PM
#3851   Just like Ariad, AUPH will burn through $200 biotech_researcher 05/21/17 08:39:30 PM
#3850   How prevalent is the disease? The Lupus Foundation of Lunacy 05/21/17 08:24:57 PM
#3849   Share dilution is not necessary to bring the vidpok45 05/21/17 08:00:26 PM
#3848   Dilution with over 200 million cash on hand! ? Pittkid 05/21/17 12:09:54 PM
#3847   I reject the premise that share dilution will northern vortex 05/21/17 11:55:29 AM
#3846   nw to the board but been trading for pac464 05/21/17 10:20:34 AM
#3845   hi guys new to the board and thanks pac464 05/21/17 10:18:56 AM
#3844   Place a high limit sell order! In this Pittkid 05/21/17 09:35:53 AM
#3843   I find their platform (SSE) to be done nsomniyak 05/20/17 10:30:15 PM
#3842   Sounds like Shwab offers a good deal. How's PositiveThoughts 05/20/17 08:47:43 PM
#3841   That might do it. I still think nsomniyak 05/20/17 08:27:53 PM
#3840   How do you keep your shares from being PositiveThoughts 05/20/17 08:23:00 PM
#3838   Maybe more than just Dry Eye Syndrome... Voclosporin is Lunacy 05/19/17 11:06:01 PM
#3836   Great question. Short answer: the smart ones do vidpok45 05/19/17 10:51:21 PM
#3834   Can be before or after, there is no nsomniyak 05/19/17 08:38:48 PM
#3833   I'm with you Tiny. I also, appreciate SantaFe Miguel 05/19/17 08:31:25 PM
#3832   Remember, ph 3 trials in many cases do biotech_researcher 05/19/17 08:26:03 PM
#3829   someone else can answer that better than me, cervelo 05/19/17 07:54:08 PM
#3828   Don't buyouts usually come before approval? Newbie1421 05/19/17 07:37:01 PM
#3827   2020 3 more years giving me a potential cervelo 05/19/17 07:05:44 PM
#3826   Excellent interview with Glicky, thanks Lunacy! 2020 approval biotech_researcher 05/19/17 05:33:50 PM
#3825   Biotech and pharma aren't my specialty. The technical TinyGreenSprout 05/19/17 03:21:06 PM
#3824   When I first got into AUPH, 7 or SantaFe Miguel 05/19/17 03:09:36 PM
#3822   I guess I'm going to have to raise Pencow 05/19/17 02:26:56 PM
#3820   Completely agree. I really did dial back trading_cyclist 05/19/17 01:37:25 PM
#3819   Even when thinking about the most conservative #s, Lunacy 05/19/17 01:13:40 PM
#3818   ...And if you really want to go crazy trading_cyclist 05/19/17 01:08:35 PM
#3817   Thanks for sharing that, I missed the interview. trading_cyclist 05/19/17 12:57:26 PM
#3816   at 40K US dollars per patient, 100k patients vidpok45 05/19/17 12:50:22 PM
#3815   That 4 billion number is in CAD. historyperson 05/19/17 12:42:28 PM
#3813   So, if we have a 4 billion vidpok45 05/19/17 12:23:06 PM
#3812   Thank you, that's very helpful information. nferna 05/19/17 11:29:28 AM
#3811   It floats week to week on each stock. nsomniyak 05/19/17 11:15:06 AM
#3810   The slide said it is a 4B market tiv111 05/19/17 11:13:44 AM
PostSubject